<DOC>
	<DOCNO>NCT00513188</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop dividing . Combinations biological substance denileukin diftitox may able carry cancer-killing substance directly non-Hodgkin lymphoma cell . Giving combination chemotherapy together denileukin diftitox may kill cancer cell . PURPOSE : This clinical trial study well give combination chemotherapy together denileukin diftitox work treat patient newly diagnose T-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Denileukin Diftitox Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate failure-free survival patient newly diagnose peripheral T-cell non-Hodgkin lymphoma treat cyclophosphamide , doxorubicin hydrochloride , vincristine , prednisone ( CHOP ) , denileukin diftitox ( Ontak® ) alternate high-dose methotrexate , leucovorin calcium , cytarabine , Ontak® ( CHOP-MONTAK regimen ) . Secondary - To determine response rate ( CR , CRu , PR ) patient . - To determine overall survival patient . - To determine toxicity profile regimen . - To correlate response CD25 expression patient . OUTLINE : - Courses 1 , 3 , 5 : Patients receive cyclophosphamide IV 30 minute , doxorubicin hydrochloride IV , vincristine IV day 1 ; oral prednisone daily day 1-5 ; denileukin diftitox IV 60 minute day 1 2 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . - Courses 2 , 4 , 6 : Patients receive high-dose methotrexate ( MTX ) IV 24 hour day 1 ; cytarabine IV 2 hour every 12 hour day 2 3 ; leucovorin calcium IV 15 minute every 6 hour 8 dos begin 12 hour last dose MTX infusion . Patients also receive denileukin diftitox IV 60 minute 2 dos MTX blood level clear . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . Patients undergo tumor tissue blood sample collection periodically correlative study . Samples analyze CD25-positive -negative expression response rate via flow cytometry . After completion study treatment , patient follow every 3 month 2 year , every 4 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis peripheral Tcell nonHodgkin lymphoma Newly diagnose , previously untreated disease Mycosis fungoides systemic disease ( i.e. , beyond skin ) allow No CD30positive ALK 1positive Tanaplastic large cell lymphoma No skin involvement No localize NK/Tcell lymphoma No adult Tcell leukemia/lymphoma No known CNS involvement PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy &gt; 3 month ANC &gt; 1,000/mm^3 ( unless due lymphoma ) Platelets &gt; 100,000/mm^3 ( unless due lymphoma ) Serum bilirubin ≤ 2.0 mg/dL ( unless due lymphoma ) Serum creatinine ≤ 1.5 mg/dL ( unless due lymphoma ) Albumin ≥ 3.0 g/dL Cardiac ejection fraction ≥ 50 % MUGA echocardiogram Not pregnant nursing Negative serum urine βHCG screen Women male partner childbearing potential must practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch ) study entry throughout study period Willing receive transfusion blood product No HIVpositive serology No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Child 's class C liver cirrhosis Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would limit study compliance No prior concurrent malignancy poor prognosis ( i.e. , &lt; 90 % probability survival 5 year ) actively treat PRIOR CONCURRENT THERAPY : No prior chemotherapy treatment lymphoma No concurrent investigational agent treatment lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
</DOC>